Sulforaphane Mediates Glutathione Depletion via Polymeric Nanoparticles to Restore Cisplatin Chemosensitivity.
暂无分享,去创建一个
S. Qi | Xuexiang Han | Yiye Li | Ying Xu | Xiao Zhao | Yinlong Zhang | Guangjun Nie | Y. Bao | Jian Shi | Yingqiu Qi | Huan Min | Xiao Zhao
[1] C. Fimognari,et al. Sulforaphane Potentiates Anticancer Effects of Doxorubicin and Cisplatin and Mitigates Their Toxic Effects , 2020, Frontiers in Pharmacology.
[2] Qiao Jiang,et al. Precise nanomedicine for intelligent therapy of cancer , 2018, Science China Chemistry.
[3] O. Farokhzad,et al. Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. , 2018, Nano letters.
[4] Yuliang Zhao,et al. Rational Design of Conjugated Photosensitizers with Controllable Photoconversion for Dually Cooperative Phototherapy , 2018, Advanced materials.
[5] K. Leong,et al. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. , 2016, Biomaterials.
[6] Chaoliang He,et al. Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[7] Kam W. Leong,et al. Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines , 2016 .
[8] Yujuan Shan,et al. Sulforaphane Protects the Liver against CdSe Quantum Dot-Induced Cytotoxicity , 2015, PloS one.
[9] Xiangliang Yang,et al. Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor. , 2015, ACS nano.
[10] T. Ji,et al. Multiple Layer‐by‐Layer Lipid‐Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models , 2015 .
[11] J. Aldrich-Wright,et al. Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment , 2014 .
[12] A. D. Di Pasqua,et al. Enhanced toxicity of cisplatin with chemosensitizer phenethyl isothiocyanate toward non-small cell lung cancer cells when delivered in liposomal nanoparticles. , 2014, Chemical Research in Toxicology.
[13] L. Galluzzi,et al. Systems biology of cisplatin resistance: past, present and future , 2014, Cell Death and Disease.
[14] Yuhua Wang,et al. Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. , 2013, ACS nano.
[15] R. Gayathri,et al. Apoptotic role of natural isothiocyanate from broccoli (Brassica oleracea italica) in experimental chemical lung carcinogenesis , 2013, Pharmaceutical biology.
[16] R. Zhao,et al. Engineering the Assemblies of Biomaterial Nanocarriers for Delivery of Multiple Theranostic Agents with Enhanced Antitumor Efficacy , 2013, Advanced materials.
[17] Weiwei Jiang,et al. A poly(γ, L-glutamic acid)-citric acid based nanoconjugate for cisplatin delivery. , 2012, Biomaterials.
[18] L. Galluzzi,et al. Molecular mechanisms of cisplatin resistance , 2012, Oncogene.
[19] M. Uesaka,et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.
[20] Guangjun Nie,et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. , 2011, Biomaterials.
[21] G. Stathopoulos,et al. Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer , 2011, Cancer Chemotherapy and Pharmacology.
[22] A. Boddy,et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours , 2011, British Journal of Cancer.
[23] Zirong Wu,et al. Poly (γ, L‐glutamic acid)‐cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: A comparative study with clinically used platinum derivatives , 2010, Cancer science.
[24] A. Kong,et al. Molecular Targets of Dietary Phenethyl Isothiocyanate and Sulforaphane for Cancer Chemoprevention , 2010, The AAPS Journal.
[25] E. Ho,et al. Multi-targeted prevention of cancer by sulforaphane. , 2008, Cancer letters.
[26] E. Jeffery,et al. Sulforaphane and erucin increase MRP1 and MRP2 in human carcinoma cell lines. , 2008, The Journal of nutritional biochemistry.
[27] L. Kèlland,et al. The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.
[28] K. Avgoustakis,et al. Effect of Conditions of Preparation on the Size and Encapsulation Properties of PLGA-mPEG Nanoparticles of Cisplatin , 2007, Drug delivery.
[29] Z. Yi,et al. Poly(gamma,L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. , 2006, Biomaterials.
[30] N. Nishiyama,et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats , 2005, British Journal of Cancer.
[31] J. Jakubikova,et al. Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. , 2005, Biochemical pharmacology.
[32] Paul J Thornalley. Isothiocyanates: mechanism of cancer chemopreventive action. , 2002, Anti-cancer drugs.
[33] N. Saijo,et al. Gamma-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. , 1995, Biochemical and biophysical research communications.
[34] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[35] M. Newman,et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.